Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

Published:2022-04 Issue:10336 Volume:399 Page:1718-1729
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Luke Jason J,Rutkowski Piotr,Queirolo Paola,Del Vecchio Michele,Mackiewicz Jacek,Chiarion-Sileni Vanna,de la Cruz Merino Luis,Khattak Muhammad A,Schadendorf Dirk,Long Georgina V,Ascierto Paolo A,Mandala Mario,De Galitiis Federica,Haydon Andrew,Dummer Reinhard,Grob Jean-Jacques,Robert Caroline,Carlino Matteo S,Mohr Peter,Poklepovic Andrew,Sondak Vernon K,Scolyer Richard A,Kirkwood John M,Chen Ke,Diede Scott J,Ahsan Sama,Ibrahim Nageatte,Eggermont Alexander M M

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. Targeted agents and immunotherapies: optimizing outcomes in melanoma;Luke;Nat Rev Clin Oncol,2017

2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

3. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

4. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

5. Improved overall survival in melanoma with combined dabrafenib and trametinib;Robert;N Engl J Med,2015

Cited by 225 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort study;EJC Skin Cancer;2024-12

2. The impact of prognostic factors and comorbidities on survival in older adults with stage I − III cutaneous melanoma in Southwest Finland: A register study;Journal of Geriatric Oncology;2024-03

3. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator;Journal of Clinical Oncology;2024-02-05

4. Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations;Translational Oncology;2024-02

5. Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma;Journal of the American Academy of Dermatology;2024-02